Clinical utility of plasma Epstein‐Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma
Open Access
Abstract
BACKGROUND: Single nucleotide polymorphism (SNP) of the excision repair cross‐complementing group 1 (ERCC1) gene has been linked with sensitivity to platinum and radiation. The authors hypothesized that the ERCC1 genotype for the SNPs cytosine‐to‐thymine substitution at codon 118 (C118T) and cytosine‐to‐adenine substitution at codon 8092 (C8092A) is prognostic in patients with nasopharyngeal carcinoma (NPC) who receive either radiotherapy (RT) or cisplatin plus RT.METHODS: The authors tested their hypothesis using biomarker screening samples from the Hong Kong NPC Study Group 0502 trial, which was a prospective, multicenter clinical trial that used post‐RT plasma Epstein‐Bar virus (EBV) DNA (pEBV) levels to screen patients with high‐risk NPC for adjuvant chemotherapy.RESULTS: ERCC1 SNPs were analyzed in 576 consecutive patients who were screened by pEBV. In the total biomarker population, there was no significant association of ERCC1 C118T or C8092A genotype with relapse‐free survival (RFS) or overall survival (OS). There also was no correlation between ERCC1 genotype and ERCC1 protein or messenger RNA expression in a subset of patients who had available paired biopsies. Post‐RT pEBV status was the only independent prognosticator for RFS and OS in multivariate analyses. However, there was a significant interaction between ERCC1 C118T genotype and post‐RT pEBV status (RFS, P = .0106; OS, P = .0067). The ERCC1 C118T genotype was significantly associated with both RFS (hazard ratio, 1.67; 95% confidence interval, 1.07‐2.61; P = .024) and OS (hazard ratio, 2.31; 95% confidence interval, 1.22‐4.40; P = .0106) in the post‐RT pEBV‐negative population, but not in the pEBV‐positive population.CONCLUSIONS: The current results prospectively validate pEBV as the most significant prognostic biomarker in NPC that can be used to select high‐risk patients for adjuvant therapy. The ERCC1 C118T genotype may help to identify a favorable subgroup (approximately 7%) of pEBV‐negative patients with NPC who have an excellent prognosis and can be spared the toxicities of further therapy. Cancer 2015;121:2720‐2729. © 2015 American Cancer SocietyKeywords
Funding Information
- central research funds CUHK & Hospital Authority
- Research Grant Council, Hong Kong SAR
This publication has 40 references indexed in Scilit:
- Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literatureLung Cancer, 2009
- A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patientsCarcinogenesis, 2008
- Current status of excision repair cross complementing-group 1 (ERCC1) in cancerCancer Treatment Reviews, 2007
- Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal CancerClinical Cancer Research, 2005
- Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancerAnnals of Oncology, 2004
- Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based ChemotherapyClinical Cancer Research, 2004
- ERCC1/ERCC4 5-endonuclease activity as a determinant of hypoxic cell radiosensitivityInternational Journal of Radiation Biology, 1996